ARCUTIS BIOTHERAPEUTICS, INC. Purchase Obligation, to be Paid, Year One
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Purchase Obligation, to be Paid, Year One of $7.50 million as of 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligationDueInNextTwelveMonths · last filed 2025-02-25
- 2024-12-31: Purchase Obligation, to be Paid, Year One $7.50M.
- 2023-12-31: Purchase Obligation, to be Paid, Year One $1.90M.
- 2023-09-30: Purchase Obligation, to be Paid, Year One $800.00K.
- 2023-06-30: Purchase Obligation, to be Paid, Year One $800.00K.
| Period end | Purchase Obligation, to be Paid, Year One |
|---|---|
| 2024-12-31 | $7.50M 10-K · filed 2025-02-25 |
| 2023-12-31 | $1.90M 10-K · filed 2024-02-27 |
| 2023-09-30 | $800.00K 10-Q · filed 2023-11-03 |
| 2023-06-30 | $800.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $800.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $3.50M 10-K · filed 2023-02-28 |
| 2022-09-30 | $2.10M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $600.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $600.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $8.20M 10-K · filed 2022-02-22 |
| 2021-09-30 | $600.00K 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |